.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Baxter
Fish and Richardson
Johnson and Johnson
Boehringer Ingelheim
US Department of Justice
Express Scripts
Deloitte
Cantor Fitzgerald
Chinese Patent Office

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202240

« Back to Dashboard
NDA 202240 describes CELECOXIB, which is a drug marketed by Alembic Pharms Ltd, Aurobindo Pharma Ltd, Lupin Ltd, Cipla Ltd, Mylan Pharms Inc, Jubilant Generics, Watson Labs Inc, Torrent Pharms Ltd, Macleods Pharms Ltd, Apotex Inc, and Teva, and is included in eleven NDAs. It is available from thirty-six suppliers. Additional details are available on the CELECOXIB profile page.

The generic ingredient in CELECOXIB is celecoxib. There are twenty-five drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

Summary for NDA: 202240

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202240

Suppliers and Packaging for NDA: 202240

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CELECOXIB
celecoxib
CAPSULE;ORAL 202240 ANDA Lupin Pharmaceuticals, Inc. 68180-395 68180-395-07 60 CAPSULE in 1 BOTTLE (68180-395-07)
CELECOXIB
celecoxib
CAPSULE;ORAL 202240 ANDA Lupin Pharmaceuticals, Inc. 68180-396 68180-396-01 100 CAPSULE in 1 BOTTLE (68180-396-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength50MG
Approval Date:Oct 29, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength100MG
Approval Date:Jun 9, 2015TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength200MG
Approval Date:Jun 9, 2015TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Dow
McKinsey
Accenture
Mallinckrodt
Queensland Health
Boehringer Ingelheim
Merck
Harvard Business School
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot